KshivetsWSCTS2023_Brazil.pdf

Oleg Kshivets
Oleg Kshivetsthoracic/abdominal/general surgeon & surgical oncologist at Siauliai Public Hospital

5-year survival of ECP after radical procedures significantly depended on: 1) PT “early-invasive cancer”; 2) PT N0--N12; 3) Cell Ratio Factors; 4) blood cell circuit; 5) biochemical factors; 6) hemostasis system; 7) AT; 8) EC characteristics; 9) EC cell dynamics; 10) tumor localization; 11) anthropometric data; 12) surgery type. Optimal diagnosis and treatment strategies for EC are: 1) screening and early detection of EC; 2) availability of experienced thoracoabdominal surgeons because of complexity of radical procedures; 3) aggressive en block surgery and adequate lymph node dissection for completeness; 4) precise prediction; 5) adjuvant chemoimmunoradiotherapy for ECP with unfavorable prognosis.

Survival of ECP, n=557
Complete Censored
-5 0 5 10 15 20 25 30 35 40
Years after Esophagogastrectomies
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
Cumulative
Proportion
Surviving
Cumulative Proportion Surviving (Kaplan-Meier)
P=0.000
Complete Censored
0 5 10 15 20 25 30 35 40
Years after Esophagogastrectomies
0.0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
Cumulative
Proportion
N 1 2
N 0
Cumulative Proportion Surviving (Kaplan-Meier)
P=0.000
Complete Censored
0 5 10 15 20 25 30 35 40
Years after Esophagogastrectomies
0.0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
Cumulative
Proportion
Surviving
Invasive Cancer
Early Cancer
Cumulative Proportion Surviving (Kaplan-Meier)
P=0.00084
Complete Censored
0 5 10 15 20 25 30 35 40
Years after Esophagogastrectomies
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
Cumulative
Proportion
Surviving
A C H I R T
Surgery
Cumulative Proportion Surviving (Kaplan-Meier)
P=0.00294
Complete Censored
0 5 10 15 20 25 30 35 40
Years after Esophagogastrectmies
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
Cumulative
Proportion
Surviving
Others
Upper/3
Cumulative Proportion Surviving (Kaplan-Meier)
P=0.000
Complete Censored
0 5 10 15 20 25 30 35 40
Years after Esophagogastrectomies
0.0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
Cumulative
Proportion
Esophageal Cancer
Cardioesophageal Cancer
Esophageal Cancer: Neural Networks, Complex System Analysis,
Statistics and Simulation Modeling for Best Management. #22247
Kshivets Oleg, MD, PhD Surgery Department, Roshal Hospital, Moscow, Russia
OBJECTIVE: 5-survival (5YS) and life span after radical surgery for esophageal cancer (EC) pa-tients (ECP) (T1-4N0-
2M0) was analyzed. The importance must be stressed of using complex system analysis, artificial intelligence (neural
networks computing), simulation modeling and statistical methods in combination, because the different approaches
yield complementary pieces of prognostic information.
METHODS: We analyzed data of 557 consecutive ECP (age=56.6±8.9 years; tumor size=6±3.5 cm) radically operated
(R0) and monitored in 1975-2023 (m=415, f=142; esophagogastrectomies (EG) Garlock=288, EG Lewis=269, combined EG
with resection of pancreas, liver, diaphragm, aorta, VCS, colon transversum, lung, trachea, pericardium,
splenectomy=168; adenocarcinoma=319, squamous=228, mix=10; T1=130, T2=115, T3=184, T4=128; N0=282, N1=70,
N2=205; G1=157, G2=142, G3=258; early EC=111, invasive=446; only surgery=425, adjuvant chemoimmunoradiotherapy-
AT=132: 5-FU+thymalin/taktivin+radiotherapy 45-50Gy). Multivariate Cox modeling, clustering, SEPATH, Monte Carlo,
bootstrap and neural networks computing were used to determine any significant dependence.
RESULTS: Overall life span (LS) was 1876.9±2219.8 days and cumulative 5-year survival (5YS) reached 52%, 10 years –
45.5%, 20 years – 33.4%, 30 years – 26.9%. 187 ECP lived more than 5 years (LS=4271±2411.9 days), 99 ECP – more than
10 years (LS=5883±2296.6 days). 228 ECP died because of EC (LS=629.8±324.1 days). AT significantly improved 5YS
(67.8% vs. 48.7%) (P=0.00084 by log-rank test). Cox modeling displayed that 5YS of ECP significantly depended on:
phase transition (PT) N0—N12 in terms of synergetics, cell ratio factors (ratio between cancer cells- CC and blood cells
subpopulations), T, G, histology, age, AT, localization, prothrombin index, hemorrhage time, residual nitrogen, protein
(P=0.000-0.019). Neural networks, genetic algorithm selection and bootstrap simulation revealed relationships between
5YS and
healthy cells/CC (rank=1), PT early-invasive EC (2); PT N0—N12 (3), erythrocytes/CC (4), thrombocytes/CC (5); stick
neutrophils/CC (6), lymphocytes/CC (7), segmented neutrophils/CC (8), eosinophils/CC (9), leucocytes/CC (10);
monocytes/CC (11). Correct prediction of 5YS was 100% by neural networks computing (area under ROC curve=1.0;
error=0.0).
CONCLUSIONS: 5-year survival of ECP after radical procedures significantly depended on: 1) PT “early-invasive
cancer”; 2) PT N0--N12; 3) Cell Ratio Factors; 4) blood cell circuit; 5) biochemical factors; 6) hemostasis system; 7) AT;
8) EC characteristics; 9) EC cell dynamics; 10) tumor localization; 11) anthropometric data; 12) surgery type. Optimal
diagnosis and treatment strategies for EC are: 1) screening and early detection of EC; 2) availability of experienced
thoracoabdominal surgeons because of complexity of radical procedures; 3) aggressive en block surgery and adequate
lymph node dissection for completeness; 4) precise prediction; 5) adjuvant chemoimmunoradiotherapy for ECP with
unfavorable prognosis.
Factors (n=413) Rank Sensitivity
Phase Transition Early---Invasive Cancer 1 24671
Healthy Cells/Cancer Cells
Erythrocytes/Cancer Cells
Phase Transition N0—N12
Thrombocytes/Cancer Cells
Segmented Neutrophils/Cancer Cells
Stick Neutrophils/Cancer Cells
Lymphocytes/Cancer Cells
Monocytes/Cancer Cells
Leucocytes/Cancer Cells
Eosinophils/Cancer Cells
2
3
4
5
6
7
8
9
10
11
23071
18425
18188
12766
7861
7164
6424
6229
5643
4982
Significant Factors (Number of Samples=3333) Rank Kendal Tau-A P
Tumor Size 1 -0.308 0.000
Healthy Cells/Cancer Cells 2 0.305 0.000
T1-4 3 -0.299 0.000
Erythrocytes/Cancer Cells 4 0.299 0.000
Leucocytes/Cancer Cells 5 0.290 0.000
Thrombocytes/Cancer Cells 6 0.285 0.000
Lymphocytes/Cancer Cells 7 0.281 0.000
Residual Nitrogen 8 -0.275 0.000
Segmented Neutrophils/Cancer Cells 9 0.273 0.000
Phase Transition N0---N12 10 -0.239 0.000
Hemorrhage Time 11 -0.228 0.000
Monocytes/Cancer Cells 12 0.227 0.000
Phase Transition Early---Invasive Cancer 13 -0.222 0.000
Esophageal/Cardioesophageal Cancer 14 -0.191 0.000
Operation Type 15 -0.187 0.000
Eosinophils/Cancer Cells 16 0.173 0.000
Stick Neutrophils/Cancer Cells 17 0.144 0.001
G1-3 18 -0.140 0.001
Tumor Growth 19 -0.113 0.01
Erythrocytes 20 0.100 0.01
Combined Procedure 21 0.095 0.01
Weight 22 0.092 0.01
Localization 23 0.069 0.05

Recommended

Kshivets_SPB_WSCTS2022Eso.pdf by
Kshivets_SPB_WSCTS2022Eso.pdfKshivets_SPB_WSCTS2022Eso.pdf
Kshivets_SPB_WSCTS2022Eso.pdfOleg Kshivets
283 views19 slides
Esophageal Cancer: Precise Prediction by
Esophageal Cancer: Precise Prediction      Esophageal Cancer: Precise Prediction
Esophageal Cancer: Precise Prediction Oleg Kshivets
98 views19 slides
Kshivets ny2021aats by
Kshivets ny2021aatsKshivets ny2021aats
Kshivets ny2021aatsOleg Kshivets
5.3K views2 slides
Kshivets O. Esophageal and Cardioesophageal Cancer Surgery by
Kshivets O. Esophageal and Cardioesophageal Cancer SurgeryKshivets O. Esophageal and Cardioesophageal Cancer Surgery
Kshivets O. Esophageal and Cardioesophageal Cancer SurgeryOleg Kshivets
1.2K views20 slides
Combined Esophagogastrectomies: Survival Outcomes in Patients with Local Adva... by
Combined Esophagogastrectomies: Survival Outcomes in Patients with Local Adva...Combined Esophagogastrectomies: Survival Outcomes in Patients with Local Adva...
Combined Esophagogastrectomies: Survival Outcomes in Patients with Local Adva...Oleg Kshivets
16.3K views1 slide
Kshivets eacts milan2018 by
Kshivets eacts milan2018Kshivets eacts milan2018
Kshivets eacts milan2018Oleg Kshivets
12K views22 slides

More Related Content

Similar to KshivetsWSCTS2023_Brazil.pdf

Kshivets milan2014 by
Kshivets milan2014Kshivets milan2014
Kshivets milan2014Oleg Kshivets
8.8K views18 slides
Kshivets iaslc denver2021 by
Kshivets iaslc denver2021Kshivets iaslc denver2021
Kshivets iaslc denver2021Oleg Kshivets
3.8K views20 slides
Kshivets sso2013 by
Kshivets sso2013Kshivets sso2013
Kshivets sso2013Oleg Kshivets
2K views24 slides
Kshivets wscts2018 ljubljana by
Kshivets wscts2018 ljubljanaKshivets wscts2018 ljubljana
Kshivets wscts2018 ljubljanaOleg Kshivets
11.1K views22 slides
Kshivets esmo2021 by
Kshivets esmo2021Kshivets esmo2021
Kshivets esmo2021Oleg Kshivets
3.9K views23 slides
Kshivets ASCVTS Moscow2018 by
Kshivets ASCVTS Moscow2018Kshivets ASCVTS Moscow2018
Kshivets ASCVTS Moscow2018Oleg Kshivets
9.3K views22 slides

Similar to KshivetsWSCTS2023_Brazil.pdf(20)

Kshivets iaslc denver2021 by Oleg Kshivets
Kshivets iaslc denver2021Kshivets iaslc denver2021
Kshivets iaslc denver2021
Oleg Kshivets3.8K views
Kshivets wscts2018 ljubljana by Oleg Kshivets
Kshivets wscts2018 ljubljanaKshivets wscts2018 ljubljana
Kshivets wscts2018 ljubljana
Oleg Kshivets11.1K views
Kshivets ASCVTS Moscow2018 by Oleg Kshivets
Kshivets ASCVTS Moscow2018Kshivets ASCVTS Moscow2018
Kshivets ASCVTS Moscow2018
Oleg Kshivets9.3K views
Kshivets O. Esophagogastric Cancer Surgery by Oleg Kshivets
Kshivets O. Esophagogastric Cancer SurgeryKshivets O. Esophagogastric Cancer Surgery
Kshivets O. Esophagogastric Cancer Surgery
Oleg Kshivets875 views
Non–Small Cell Lung Cancer by fondas vakalis
Non–Small Cell Lung CancerNon–Small Cell Lung Cancer
Non–Small Cell Lung Cancer
fondas vakalis2.4K views
2021 esmo world_gi_poster_kshivets by Oleg Kshivets
2021 esmo world_gi_poster_kshivets2021 esmo world_gi_poster_kshivets
2021 esmo world_gi_poster_kshivets
Oleg Kshivets8.7K views
Gene Profiling in Clinical Oncology - Slide 2 - T. Le Chevalier - Treatment o... by European School of Oncology
Gene Profiling in Clinical Oncology - Slide 2 - T. Le Chevalier - Treatment o...Gene Profiling in Clinical Oncology - Slide 2 - T. Le Chevalier - Treatment o...
Gene Profiling in Clinical Oncology - Slide 2 - T. Le Chevalier - Treatment o...
Kshivets barcelona2019 by Oleg Kshivets
Kshivets barcelona2019Kshivets barcelona2019
Kshivets barcelona2019
Oleg Kshivets9.9K views
Kshivets Hong Kong Sydney2020 by Oleg Kshivets
Kshivets Hong Kong Sydney2020Kshivets Hong Kong Sydney2020
Kshivets Hong Kong Sydney2020
Oleg Kshivets27.8K views
Kshivets O. Lung Cancer Surgery by Oleg Kshivets
Kshivets O. Lung Cancer SurgeryKshivets O. Lung Cancer Surgery
Kshivets O. Lung Cancer Surgery
Oleg Kshivets1.8K views
4-yr OS after 2nd-line Nivolumab, pooled analysis (based on Scott Antonia pre... by Mauricio Lema
4-yr OS after 2nd-line Nivolumab, pooled analysis (based on Scott Antonia pre...4-yr OS after 2nd-line Nivolumab, pooled analysis (based on Scott Antonia pre...
4-yr OS after 2nd-line Nivolumab, pooled analysis (based on Scott Antonia pre...
Mauricio Lema560 views
Kshivets O. Esophageal & Cardioesophageal Cancer Surgery by Oleg Kshivets
Kshivets O.  Esophageal & Cardioesophageal Cancer SurgeryKshivets O.  Esophageal & Cardioesophageal Cancer Surgery
Kshivets O. Esophageal & Cardioesophageal Cancer Surgery
Oleg Kshivets748 views
Lung Cancer: 10-Year Survival by Oleg Kshivets
Lung Cancer: 10-Year Survival           Lung Cancer: 10-Year Survival
Lung Cancer: 10-Year Survival
Oleg Kshivets40.2K views
Kshivets barcelona2017 by Oleg Kshivets
Kshivets barcelona2017Kshivets barcelona2017
Kshivets barcelona2017
Oleg Kshivets5.1K views

More from Oleg Kshivets

Kshivets_IASLC_Singapore2023.pdf by
Kshivets_IASLC_Singapore2023.pdfKshivets_IASLC_Singapore2023.pdf
Kshivets_IASLC_Singapore2023.pdfOleg Kshivets
279 views18 slides
Kshivets_WCGIC2023.pdf by
Kshivets_WCGIC2023.pdfKshivets_WCGIC2023.pdf
Kshivets_WCGIC2023.pdfOleg Kshivets
407 views2 slides
Kshivets_SPB_WSCTS2022Lung.pdf by
Kshivets_SPB_WSCTS2022Lung.pdfKshivets_SPB_WSCTS2022Lung.pdf
Kshivets_SPB_WSCTS2022Lung.pdfOleg Kshivets
275 views19 slides
Survival of Lung Cancer Patients after Lobectomies was Significantly Superior... by
Survival of Lung Cancer Patients after Lobectomies was Significantly Superior...Survival of Lung Cancer Patients after Lobectomies was Significantly Superior...
Survival of Lung Cancer Patients after Lobectomies was Significantly Superior...Oleg Kshivets
78 views19 slides
Kshivets elcc2022 by
Kshivets elcc2022Kshivets elcc2022
Kshivets elcc2022Oleg Kshivets
691 views1 slide
Kshivets gc 10_ys_wjarr-2021-0659 by
Kshivets gc 10_ys_wjarr-2021-0659Kshivets gc 10_ys_wjarr-2021-0659
Kshivets gc 10_ys_wjarr-2021-0659Oleg Kshivets
4.9K views13 slides

More from Oleg Kshivets(16)

Kshivets_IASLC_Singapore2023.pdf by Oleg Kshivets
Kshivets_IASLC_Singapore2023.pdfKshivets_IASLC_Singapore2023.pdf
Kshivets_IASLC_Singapore2023.pdf
Oleg Kshivets279 views
Kshivets_SPB_WSCTS2022Lung.pdf by Oleg Kshivets
Kshivets_SPB_WSCTS2022Lung.pdfKshivets_SPB_WSCTS2022Lung.pdf
Kshivets_SPB_WSCTS2022Lung.pdf
Oleg Kshivets275 views
Survival of Lung Cancer Patients after Lobectomies was Significantly Superior... by Oleg Kshivets
Survival of Lung Cancer Patients after Lobectomies was Significantly Superior...Survival of Lung Cancer Patients after Lobectomies was Significantly Superior...
Survival of Lung Cancer Patients after Lobectomies was Significantly Superior...
Oleg Kshivets78 views
Kshivets gc 10_ys_wjarr-2021-0659 by Oleg Kshivets
Kshivets gc 10_ys_wjarr-2021-0659Kshivets gc 10_ys_wjarr-2021-0659
Kshivets gc 10_ys_wjarr-2021-0659
Oleg Kshivets4.9K views
Kshivets lc10 ys_wjarr by Oleg Kshivets
Kshivets lc10 ys_wjarrKshivets lc10 ys_wjarr
Kshivets lc10 ys_wjarr
Oleg Kshivets5.8K views
Kshivets iaslc singapore2020 by Oleg Kshivets
Kshivets iaslc singapore2020Kshivets iaslc singapore2020
Kshivets iaslc singapore2020
Oleg Kshivets29.6K views
Kshivets barcelona2020 by Oleg Kshivets
Kshivets barcelona2020Kshivets barcelona2020
Kshivets barcelona2020
Oleg Kshivets21.8K views
Kshivets ASCO Chicago2020 by Oleg Kshivets
Kshivets ASCO Chicago2020Kshivets ASCO Chicago2020
Kshivets ASCO Chicago2020
Oleg Kshivets20.1K views
Kshivets aats new_york2019 by Oleg Kshivets
Kshivets aats new_york2019Kshivets aats new_york2019
Kshivets aats new_york2019
Oleg Kshivets29.8K views
Kshivets IASLC 2019 by Oleg Kshivets
Kshivets IASLC 2019Kshivets IASLC 2019
Kshivets IASLC 2019
Oleg Kshivets12.1K views
Kshivets wscts2019 sofia by Oleg Kshivets
Kshivets wscts2019 sofiaKshivets wscts2019 sofia
Kshivets wscts2019 sofia
Oleg Kshivets10.9K views
Kshivets aats new_york2018 by Oleg Kshivets
Kshivets aats new_york2018Kshivets aats new_york2018
Kshivets aats new_york2018
Oleg Kshivets12.1K views
Kshivets iaslc toronto2018 by Oleg Kshivets
Kshivets iaslc toronto2018Kshivets iaslc toronto2018
Kshivets iaslc toronto2018
Oleg Kshivets10.8K views
Kshivets yokohama iaslc2017 by Oleg Kshivets
Kshivets yokohama iaslc2017Kshivets yokohama iaslc2017
Kshivets yokohama iaslc2017
Oleg Kshivets4.1K views

Recently uploaded

corticosteroids.pptx by
corticosteroids.pptxcorticosteroids.pptx
corticosteroids.pptxRAJ K. MAURYA
51 views26 slides
FAT ATER SOND WALUBLE VITAMINS by
FAT ATER SOND WALUBLE VITAMINS  FAT ATER SOND WALUBLE VITAMINS
FAT ATER SOND WALUBLE VITAMINS BeshedaWedajo
7 views18 slides
Peptic ulcer.pdf by
Peptic ulcer.pdfPeptic ulcer.pdf
Peptic ulcer.pdfUVAS
12 views64 slides
T1DM case example.pptx by
T1DM case example.pptxT1DM case example.pptx
T1DM case example.pptxNguyễn đình Đức
40 views17 slides
Drug induced hepatitis.pptx by
Drug induced hepatitis.pptxDrug induced hepatitis.pptx
Drug induced hepatitis.pptxImanShafqat
8 views27 slides
definition of Femoroacetabular impingement.pptx by
definition of Femoroacetabular impingement.pptxdefinition of Femoroacetabular impingement.pptx
definition of Femoroacetabular impingement.pptxHome
6 views15 slides

Recently uploaded(20)

FAT ATER SOND WALUBLE VITAMINS by BeshedaWedajo
FAT ATER SOND WALUBLE VITAMINS  FAT ATER SOND WALUBLE VITAMINS
FAT ATER SOND WALUBLE VITAMINS
BeshedaWedajo7 views
Peptic ulcer.pdf by UVAS
Peptic ulcer.pdfPeptic ulcer.pdf
Peptic ulcer.pdf
UVAS12 views
Drug induced hepatitis.pptx by ImanShafqat
Drug induced hepatitis.pptxDrug induced hepatitis.pptx
Drug induced hepatitis.pptx
ImanShafqat8 views
definition of Femoroacetabular impingement.pptx by Home
definition of Femoroacetabular impingement.pptxdefinition of Femoroacetabular impingement.pptx
definition of Femoroacetabular impingement.pptx
Home6 views
When HER2 Is Low or Negative: Emerging Evidence on Antibody-Drug Conjugates f... by PeerVoice
When HER2 Is Low or Negative: Emerging Evidence on Antibody-Drug Conjugates f...When HER2 Is Low or Negative: Emerging Evidence on Antibody-Drug Conjugates f...
When HER2 Is Low or Negative: Emerging Evidence on Antibody-Drug Conjugates f...
PeerVoice6 views
PATIENTCOUNSELLING in.pptx by skShashi1
PATIENTCOUNSELLING  in.pptxPATIENTCOUNSELLING  in.pptx
PATIENTCOUNSELLING in.pptx
skShashi126 views
VarSeq 2.5.0: VSClinical AMP Workflow from the User Perspective by Golden Helix
VarSeq 2.5.0: VSClinical AMP Workflow from the User PerspectiveVarSeq 2.5.0: VSClinical AMP Workflow from the User Perspective
VarSeq 2.5.0: VSClinical AMP Workflow from the User Perspective
Golden Helix88 views
Diagnosis of tumor.ppt by Sekaran T
Diagnosis of tumor.pptDiagnosis of tumor.ppt
Diagnosis of tumor.ppt
Sekaran T6 views
Depression PPT template by EmanMegahed6
Depression PPT templateDepression PPT template
Depression PPT template
EmanMegahed622 views
Explore new Frontiers in Medicine with AI.pdf by Anne Marie
Explore new Frontiers in Medicine with AI.pdfExplore new Frontiers in Medicine with AI.pdf
Explore new Frontiers in Medicine with AI.pdf
Anne Marie12 views
Save 20% on our supplements for kids by novaferrum
Save 20% on our supplements for kidsSave 20% on our supplements for kids
Save 20% on our supplements for kids
novaferrum7 views
DEBATE IN CA BLADDER TMT VS CYSTECTOMY by Kanhu Charan
DEBATE IN CA BLADDER TMT VS CYSTECTOMYDEBATE IN CA BLADDER TMT VS CYSTECTOMY
DEBATE IN CA BLADDER TMT VS CYSTECTOMY
Kanhu Charan50 views

KshivetsWSCTS2023_Brazil.pdf

  • 1. Survival of ECP, n=557 Complete Censored -5 0 5 10 15 20 25 30 35 40 Years after Esophagogastrectomies 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1.0 Cumulative Proportion Surviving Cumulative Proportion Surviving (Kaplan-Meier) P=0.000 Complete Censored 0 5 10 15 20 25 30 35 40 Years after Esophagogastrectomies 0.0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1.0 Cumulative Proportion N 1 2 N 0 Cumulative Proportion Surviving (Kaplan-Meier) P=0.000 Complete Censored 0 5 10 15 20 25 30 35 40 Years after Esophagogastrectomies 0.0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1.0 Cumulative Proportion Surviving Invasive Cancer Early Cancer Cumulative Proportion Surviving (Kaplan-Meier) P=0.00084 Complete Censored 0 5 10 15 20 25 30 35 40 Years after Esophagogastrectomies 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1.0 Cumulative Proportion Surviving A C H I R T Surgery Cumulative Proportion Surviving (Kaplan-Meier) P=0.00294 Complete Censored 0 5 10 15 20 25 30 35 40 Years after Esophagogastrectmies 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1.0 Cumulative Proportion Surviving Others Upper/3 Cumulative Proportion Surviving (Kaplan-Meier) P=0.000 Complete Censored 0 5 10 15 20 25 30 35 40 Years after Esophagogastrectomies 0.0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1.0 Cumulative Proportion Esophageal Cancer Cardioesophageal Cancer Esophageal Cancer: Neural Networks, Complex System Analysis, Statistics and Simulation Modeling for Best Management. #22247 Kshivets Oleg, MD, PhD Surgery Department, Roshal Hospital, Moscow, Russia OBJECTIVE: 5-survival (5YS) and life span after radical surgery for esophageal cancer (EC) pa-tients (ECP) (T1-4N0- 2M0) was analyzed. The importance must be stressed of using complex system analysis, artificial intelligence (neural networks computing), simulation modeling and statistical methods in combination, because the different approaches yield complementary pieces of prognostic information. METHODS: We analyzed data of 557 consecutive ECP (age=56.6±8.9 years; tumor size=6±3.5 cm) radically operated (R0) and monitored in 1975-2023 (m=415, f=142; esophagogastrectomies (EG) Garlock=288, EG Lewis=269, combined EG with resection of pancreas, liver, diaphragm, aorta, VCS, colon transversum, lung, trachea, pericardium, splenectomy=168; adenocarcinoma=319, squamous=228, mix=10; T1=130, T2=115, T3=184, T4=128; N0=282, N1=70, N2=205; G1=157, G2=142, G3=258; early EC=111, invasive=446; only surgery=425, adjuvant chemoimmunoradiotherapy- AT=132: 5-FU+thymalin/taktivin+radiotherapy 45-50Gy). Multivariate Cox modeling, clustering, SEPATH, Monte Carlo, bootstrap and neural networks computing were used to determine any significant dependence. RESULTS: Overall life span (LS) was 1876.9±2219.8 days and cumulative 5-year survival (5YS) reached 52%, 10 years – 45.5%, 20 years – 33.4%, 30 years – 26.9%. 187 ECP lived more than 5 years (LS=4271±2411.9 days), 99 ECP – more than 10 years (LS=5883±2296.6 days). 228 ECP died because of EC (LS=629.8±324.1 days). AT significantly improved 5YS (67.8% vs. 48.7%) (P=0.00084 by log-rank test). Cox modeling displayed that 5YS of ECP significantly depended on: phase transition (PT) N0—N12 in terms of synergetics, cell ratio factors (ratio between cancer cells- CC and blood cells subpopulations), T, G, histology, age, AT, localization, prothrombin index, hemorrhage time, residual nitrogen, protein (P=0.000-0.019). Neural networks, genetic algorithm selection and bootstrap simulation revealed relationships between 5YS and healthy cells/CC (rank=1), PT early-invasive EC (2); PT N0—N12 (3), erythrocytes/CC (4), thrombocytes/CC (5); stick neutrophils/CC (6), lymphocytes/CC (7), segmented neutrophils/CC (8), eosinophils/CC (9), leucocytes/CC (10); monocytes/CC (11). Correct prediction of 5YS was 100% by neural networks computing (area under ROC curve=1.0; error=0.0). CONCLUSIONS: 5-year survival of ECP after radical procedures significantly depended on: 1) PT “early-invasive cancer”; 2) PT N0--N12; 3) Cell Ratio Factors; 4) blood cell circuit; 5) biochemical factors; 6) hemostasis system; 7) AT; 8) EC characteristics; 9) EC cell dynamics; 10) tumor localization; 11) anthropometric data; 12) surgery type. Optimal diagnosis and treatment strategies for EC are: 1) screening and early detection of EC; 2) availability of experienced thoracoabdominal surgeons because of complexity of radical procedures; 3) aggressive en block surgery and adequate lymph node dissection for completeness; 4) precise prediction; 5) adjuvant chemoimmunoradiotherapy for ECP with unfavorable prognosis. Factors (n=413) Rank Sensitivity Phase Transition Early---Invasive Cancer 1 24671 Healthy Cells/Cancer Cells Erythrocytes/Cancer Cells Phase Transition N0—N12 Thrombocytes/Cancer Cells Segmented Neutrophils/Cancer Cells Stick Neutrophils/Cancer Cells Lymphocytes/Cancer Cells Monocytes/Cancer Cells Leucocytes/Cancer Cells Eosinophils/Cancer Cells 2 3 4 5 6 7 8 9 10 11 23071 18425 18188 12766 7861 7164 6424 6229 5643 4982 Significant Factors (Number of Samples=3333) Rank Kendal Tau-A P Tumor Size 1 -0.308 0.000 Healthy Cells/Cancer Cells 2 0.305 0.000 T1-4 3 -0.299 0.000 Erythrocytes/Cancer Cells 4 0.299 0.000 Leucocytes/Cancer Cells 5 0.290 0.000 Thrombocytes/Cancer Cells 6 0.285 0.000 Lymphocytes/Cancer Cells 7 0.281 0.000 Residual Nitrogen 8 -0.275 0.000 Segmented Neutrophils/Cancer Cells 9 0.273 0.000 Phase Transition N0---N12 10 -0.239 0.000 Hemorrhage Time 11 -0.228 0.000 Monocytes/Cancer Cells 12 0.227 0.000 Phase Transition Early---Invasive Cancer 13 -0.222 0.000 Esophageal/Cardioesophageal Cancer 14 -0.191 0.000 Operation Type 15 -0.187 0.000 Eosinophils/Cancer Cells 16 0.173 0.000 Stick Neutrophils/Cancer Cells 17 0.144 0.001 G1-3 18 -0.140 0.001 Tumor Growth 19 -0.113 0.01 Erythrocytes 20 0.100 0.01 Combined Procedure 21 0.095 0.01 Weight 22 0.092 0.01 Localization 23 0.069 0.05